Guest User 6/8/23 Guest User 6/8/23 Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines—Weiss 2022 Read More Guest User 6/8/23 Guest User 6/8/23 Primary Human Neutrophils Exhibit a Unique HIV-Directed Antibody-Dependent Phagocytosis Profile—Powell 2019 Read More Guest User 6/8/23 Guest User 6/8/23 Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk—Fox 2020 Read More Guest User 6/8/23 Guest User 6/8/23 Immune Correlates of Disease Progression in Linked HIV-1 Infection—Tuen 2019 Read More Guest User 6/8/23 Guest User 6/8/23 Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination—Polonis 2008 Read More Guest User 6/8/23 Guest User 6/8/23 Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus—Zolla-Pazner 1987 Read More Guest User 6/8/23 Guest User 6/8/23 Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon—Liu 2019 Read More Guest User 6/8/23 Guest User 6/8/23 Identifying epitopes of HIV-1 that induce protective antibodies—Zolla-Pazner 2004 Read More Guest User 6/8/23 Guest User 6/8/23 B cells in the pathogenesis of AIDS—Zolla-Pazner 1984 Read More Guest User 6/8/23 Guest User 6/8/23 The implications of antigenic diversity for vaccine development—Zolla-Pazner 1999 Read More Guest User 6/8/23 Guest User 6/8/23 Mechanisms contributing to the neutralization of HIV-1—Zolla-Pazner 1996 Read More Guest User 6/8/23 Guest User 6/8/23 Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design—Zolla-Pazner 2010 Read More Guest User 6/8/23 Guest User 6/8/23 Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV—Zolla-Pazner 2019 Read More Guest User 6/8/23 Guest User 6/8/23 Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers—Yang 2022 Read More Guest User 6/8/23 Guest User 6/8/23 Immunosuppression and infection in multiple myeloma—Jacobson 1986 Read More Guest User 6/8/23 Guest User 6/8/23 Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates—Zolla-Pazner 2016 Read More Guest User 6/8/23 Guest User 6/8/23 A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials—Zolla-Pazner 2021 Read More Guest User 6/8/23 Guest User 6/8/23 HIV-1 Vpu restricts Fc-mediated effector functions in vivo—Prevost 2022 Read More Guest User 6/8/23 Guest User 6/8/23 Template (Copy) Read More Guest User 6/8/23 Guest User 6/8/23 Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D—Conley 1994 Read More Older Posts
Guest User 6/8/23 Guest User 6/8/23 Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines—Weiss 2022 Read More
Guest User 6/8/23 Guest User 6/8/23 Primary Human Neutrophils Exhibit a Unique HIV-Directed Antibody-Dependent Phagocytosis Profile—Powell 2019 Read More
Guest User 6/8/23 Guest User 6/8/23 Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk—Fox 2020 Read More
Guest User 6/8/23 Guest User 6/8/23 Immune Correlates of Disease Progression in Linked HIV-1 Infection—Tuen 2019 Read More
Guest User 6/8/23 Guest User 6/8/23 Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination—Polonis 2008 Read More
Guest User 6/8/23 Guest User 6/8/23 Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus—Zolla-Pazner 1987 Read More
Guest User 6/8/23 Guest User 6/8/23 Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon—Liu 2019 Read More
Guest User 6/8/23 Guest User 6/8/23 Identifying epitopes of HIV-1 that induce protective antibodies—Zolla-Pazner 2004 Read More
Guest User 6/8/23 Guest User 6/8/23 The implications of antigenic diversity for vaccine development—Zolla-Pazner 1999 Read More
Guest User 6/8/23 Guest User 6/8/23 Mechanisms contributing to the neutralization of HIV-1—Zolla-Pazner 1996 Read More
Guest User 6/8/23 Guest User 6/8/23 Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design—Zolla-Pazner 2010 Read More
Guest User 6/8/23 Guest User 6/8/23 Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV—Zolla-Pazner 2019 Read More
Guest User 6/8/23 Guest User 6/8/23 Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers—Yang 2022 Read More
Guest User 6/8/23 Guest User 6/8/23 Immunosuppression and infection in multiple myeloma—Jacobson 1986 Read More
Guest User 6/8/23 Guest User 6/8/23 Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates—Zolla-Pazner 2016 Read More
Guest User 6/8/23 Guest User 6/8/23 A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials—Zolla-Pazner 2021 Read More
Guest User 6/8/23 Guest User 6/8/23 HIV-1 Vpu restricts Fc-mediated effector functions in vivo—Prevost 2022 Read More
Guest User 6/8/23 Guest User 6/8/23 Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D—Conley 1994 Read More